TG Therapeutics (NASDAQ:TGTX) Releases Quarterly Earnings Results

Key Points

• TG Therapeutics reported quarterly earnings of $0.17 per share, missing estimates by $0.10 EPS.
• The company's stock has a market cap of $5.56 billion and is trading with a P/E ratio of 145.92.
• Goldman Sachs upgraded TG Therapeutics to a "hold" rating with a price target of $37.00 while the consensus price target is $43.80.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) posted its quarterly earnings results on Monday. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.15), Zacks reports. TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The company had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. During the same period in the prior year, the company posted $0.04 EPS. TG Therapeutics's quarterly revenue was up 92.1% on a year-over-year basis. TG Therapeutics updated its FY 2025 guidance to EPS.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $30.62 on Monday. TG Therapeutics has a fifty-two week low of $16.65 and a fifty-two week high of $46.48. The stock's 50-day moving average is $36.83 and its two-hundred day moving average is $36.10. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.02 and a quick ratio of 3.04. The firm has a market cap of $4.86 billion, a P/E ratio of 127.73 and a beta of 1.95.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a research note on Thursday, July 10th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $43.80.

Insiders Place Their Bets

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the firm's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the transaction, the director directly owned 228,816 shares in the company, valued at $8,452,463.04. This trade represents a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.64% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TG Therapeutics

Institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC grew its position in shares of TG Therapeutics by 9.6% in the first quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company's stock valued at $299,000 after purchasing an additional 665 shares during the last quarter. Royal Bank of Canada grew its position in shares of TG Therapeutics by 16.4% in the first quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company's stock valued at $2,985,000 after purchasing an additional 10,660 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of TG Therapeutics by 5.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company's stock valued at $11,319,000 after purchasing an additional 14,689 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of TG Therapeutics by 21.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company's stock valued at $75,683,000 after purchasing an additional 345,059 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.